These preclinical findings have important implications for acute treatment of ischemic stroke in the clinical setting as both brain edema and haemorrhagic transformation are complications that can be aggravated by recombinant tissue plasminogen activator (rt-PA)—a thrombolytic drug, when administered outside the therapeutic time window [42]. The gene discussed is PLAT; the disease is ischemic stroke.